Hong Kong Stocks Movement | HENLIUS (02696) Surges Over 8% Intraday as HLX43 Completes First US Patient Dosing, Three Core Products to Be Featured at WCLC

Stock News

Aug 29

HENLIUS (02696) surged over 8% intraday, closing up 5.34% at HK$77.95 with a turnover of HK$90.26 million as of press time.

On the news front, HENLIUS announced that it recently completed the first patient dosing in the United States for its international multicenter Phase 2 clinical study of HLX43 injection (a PD-L1 antibody-drug conjugate targeting advanced non-small cell lung cancer (NSCLC) patients). CMB International issued a research report stating that as HENLIUS's biosimilars continue to generate cash flows in China and globally, the group is evolving into an innovative biologics company led by HLX43.

Notably, the official website of the 2025 World Conference on Lung Cancer (WCLC) recently announced selected abstracts, with HENLIUS successfully having 10 lung cancer research studies selected. The selected studies focus on three core innovative drugs: the anti-PD-1 monoclonal antibody serplulimab, the anti-EGFR monoclonal antibody HLX07, and HLX43, the world's first PD-L1 ADC to enter Phase 2 clinical trials.

Citi indicated that HENLIUS is set to release the latest data on HLX43 at WCLC, which will further reveal its potential in non-small cell lung cancer (NSCLC) treatment. If HLX43 can maintain an objective response rate (ORR) of 35% to 40% and a median progression-free survival (mPFS) of approximately 5.5 months in more diverse samples, such data would be highly compelling.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1185788130"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185788130\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185788130?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 15:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185788130","market":"hk","top_or_hot":-1,"title":"Hong Kong Stocks Movement | HENLIUS (02696) Surges Over 8% Intraday as HLX43 Completes First US Patient Dosing, Three Core Products to Be Featured at WCLC","media":"Stock News","content":"<p>HENLIUS (02696) surged over 8% intraday, closing up 5.34% at HK$77.95 with a turnover of HK$90.26 million as of press time.</p>\n<p>On the news front, HENLIUS announced that it recently completed the first patient dosing in the United States for its international multicenter Phase 2 clinical study of HLX43 injection (a PD-L1 antibody-drug conjugate targeting advanced non-small cell lung cancer (NSCLC) patients). CMB International issued a research report stating that as HENLIUS's biosimilars continue to generate cash flows in China and globally, the group is evolving into an innovative biologics company led by HLX43.</p>\n<p>Notably, the official website of the 2025 World Conference on Lung Cancer (WCLC) recently announced selected abstracts, with HENLIUS successfully having 10 lung cancer research studies selected. The selected studies focus on three core innovative drugs: the anti-PD-1 monoclonal antibody serplulimab, the anti-EGFR monoclonal antibody HLX07, and HLX43, the world's first PD-L1 ADC to enter Phase 2 clinical trials.</p>\n<p>Citi indicated that HENLIUS is set to release the latest data on HLX43 at WCLC, which will further reveal its potential in non-small cell lung cancer (NSCLC) treatment. If HLX43 can maintain an objective response rate (ORR) of 35% to 40% and a median progression-free survival (mPFS) of approximately 5.5 months in more diverse samples, such data would be highly compelling.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stocks Movement | HENLIUS (02696) Surges Over 8% Intraday as HLX43 Completes First US Patient Dosing, Three Core Products to Be Featured at WCLC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stocks Movement | HENLIUS (02696) Surges Over 8% Intraday as HLX43 Completes First US Patient Dosing, Three Core Products to Be Featured at WCLC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-29 15:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENLIUS (02696) surged over 8% intraday, closing up 5.34% at HK$77.95 with a turnover of HK$90.26 million as of press time.</p>\n<p>On the news front, HENLIUS announced that it recently completed the first patient dosing in the United States for its international multicenter Phase 2 clinical study of HLX43 injection (a PD-L1 antibody-drug conjugate targeting advanced non-small cell lung cancer (NSCLC) patients). CMB International issued a research report stating that as HENLIUS's biosimilars continue to generate cash flows in China and globally, the group is evolving into an innovative biologics company led by HLX43.</p>\n<p>Notably, the official website of the 2025 World Conference on Lung Cancer (WCLC) recently announced selected abstracts, with HENLIUS successfully having 10 lung cancer research studies selected. The selected studies focus on three core innovative drugs: the anti-PD-1 monoclonal antibody serplulimab, the anti-EGFR monoclonal antibody HLX07, and HLX43, the world's first PD-L1 ADC to enter Phase 2 clinical trials.</p>\n<p>Citi indicated that HENLIUS is set to release the latest data on HLX43 at WCLC, which will further reveal its potential in non-small cell lung cancer (NSCLC) treatment. If HLX43 can maintain an objective response rate (ORR) of 35% to 40% and a median progression-free survival (mPFS) of approximately 5.5 months in more diverse samples, such data would be highly compelling.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1185788130","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185788130","pubTimestamp":1756453735,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENLIUS (02696) surged over 8% intraday, closing up 5.34% at HK$77.95 with a turnover of HK$90.26 million as of press time. On the news front, HENLIUS announced that it recently completed the first...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02696":"复宏汉霖"},"translate_title":"港股动向|复宏汉霖(02696)盘中大涨超8%HLX43完成首次美国患者给药三大核心产品亮相WCLC","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"HENLIUS (02696) surged over 8% intraday, closing up 5.34% at HK$77.95 with a turnover of HK$90.26 million as of press time.\nOn the news front, HENLIUS announced that it recently completed the first patient dosing in the United States for its international multicenter Phase 2 clinical study of HLX43 injection (a PD-L1 antibody-drug conjugate targeting advanced non-small cell lung cancer (NSCLC) patients). CMB International issued a research report stating that as HENLIUS's biosimilars continue to generate cash flows in China and globally, the group is evolving into an innovative biologics company led by HLX43.\nNotably, the official website of the 2025 World Conference on Lung Cancer (WCLC) recently announced selected abstracts, with HENLIUS successfully having 10 lung cancer research studies selected. The selected studies focus on three core innovative drugs: the anti-PD-1 monoclonal antibody serplulimab, the anti-EGFR monoclonal antibody HLX07, and HLX43, the world's first PD-L1 ADC to enter Phase 2 clinical trials.\nCiti indicated that HENLIUS is set to release the latest data on HLX43 at WCLC, which will further reveal its potential in non-small cell lung cancer (NSCLC) treatment. If HLX43 can maintain an objective response rate (ORR) of 35% to 40% and a median progression-free survival (mPFS) of approximately 5.5 months in more diverse samples, such data would be highly compelling.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}